Immatics Reports Q1 2026 Results, Highlights Key Clinical Milestones & Extends Cash Runway
IMTX has more than doubled off its 52-week low of $4.15.
Summary
Immatics N.V. reported an increased net loss in Q1 2026 but confirmed a strong cash runway into 2028 and outlined critical upcoming clinical milestones for its PRAME franchise, including Phase 3 data for anzu-cel in 2026.
Key Events · Earnings and Guidance · IMTX
-
Q1 2026 Financial Results
Net loss increased to €57.8 million for Q1 2026, up from €39.9 million in Q1 2025, driven by higher research and development expenses as clinical trials advance.
-
Extended Cash Runway
Cash and other financial assets totaled €453.6 million as of March 31, 2026, with a projected cash reach into 2028, providing a solid financial foundation for ongoing operations.
-
Phase 3 Trial Progress for Anzu-cel
Interim and final data analyses for the Phase 3 SUPRAME trial of anzu-cel (PRAME cell therapy) are expected to be triggered in 2026, with BLA submission targeted for H1 2027 and commercial launch in H2 2027.
-
Multiple Upcoming Clinical Data & Trials
Several key clinical data readouts are expected in 2026 across the PRAME franchise, including for IMA203CD8 and IMA402, and a new Phase 1 combination trial for IMA401/IMA402 bispecifics is set to begin mid-2026.
Analysis · IMTX · Life Sciences
Immatics N.V. reported an increased net loss for Q1 2026, primarily due to higher research and development expenses as it advances its clinical pipeline. However, the company maintains a strong cash position, projected to fund operations into 2028, which is critical for a clinical-stage biotech. The filing provides a clear roadmap of significant upcoming clinical milestones, including the anticipated Phase 3 data trigger for its lead PRAME cell therapy, anzu-cel, in 2026, and plans for BLA submission and commercial launch in 2027. These clinical catalysts are key drivers for future valuation.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 37.2% of the 984 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.83%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMTX was trading at $11.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $4.15 to $12.41. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.